This also includes composition of matter claims for MK-specific antibodies, including Cellmid's lead humanised antibody CAB102.
The granted claims cover the use of any such antibodies for prevention and treatment of cancer, autoimmune diseases, inflammatory diseases, and any disease or disorder attributed to cell migration.
This follows on patents already in force in Europe, Australia and Japan.
In numerous published studies, the MK C-domain has been demonstrated as the key region promoting signalling and pathology attributed to MK. Blocking the C-domain therefore represents a powerful potential treatment option in many MK-related diseases as has been shown in a number of animal models.
Maria Halasz, chief executive officer, said:
"Having this patent granted in U.S. for our MK antibodies across such a wide array of diseases is a tremendous commercial outcome for Cellmid.
"This patent adds to already covered territories of Europe, Japan and Australia. This family gives Cellmid strong and exclusive rights to develop MK antibodies unencumbered by competition.
"Moreover, Cellmid's patent coverage for its therapeutic antibodies now extends across cancer, inflammatory and autoimmune diseases, and surgical adhesion."
Cellmid holds the most significant intellectual property assets related to MK worldwide.
Its patent portfolio currently includes 88 patents in 21 patent families, which cover use of MK and anti-MK agents for therapeutic purposes in a number of diseases, as well as the use of MK as a diagnostic marker in cancer and other disorders.
Last week, the company made changes to its board to reflect its focus on accelerating the expansion of its consumer health business.
Graeme Kaufman and Martin Rogers have stepped down as non-executive directors of the company with effect from 30th June 2015 while Bruce Gordon will be appointed as a non-executive director from 1st July 2015.
Gordon has over 25 years of audit and finance experience in industries such as retail, healthcare, resources and manufacturing.
Earlier this month, Cellmid secured a $1 million research and development loan funding from Platinum Road that along with existing resources will allow it to accelerate the successful launch campaign of its évolis® hair growth products and proceed with the toxicology component of its preclinical anti-midkine antibody program.
Cellmid's lead humanised antibody CAB102 has showed no dose limiting toxicities in formal safety and toxicology studies performed in rats and non-human primates (cynomolgus macaques).
The results de-risk midkine as a therapeutic target and pave the way for its antibody program to proceed towards clinical studies.
Single doses of CAB102 were administered by intravenous infusion at 3 dose levels, 10, 50 or 100mg/kg.
Animals were monitored for 14 days post-dose for clinical observations, morbidities, weight changes, clinical chemistries and blood cell counts.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.